Tirzepatide Slows CKD Progression among diabetes patients with Increased CV risk Dr. Kamal Kant Kohli7 Jun 2022 3:45 AM GMTTirzepatide can slow progression of chronic kidney disease in type 2 diabetes according to an analysis of SURPASS-4 data presented at ADA 2022. In...
Tirzepatide new treatment option for people who are overweight or have obesity: SURMOUNT-1 clinical trial Dr. Kamal Kant Kohli6 Jun 2022 4:15 AM GMTIn the 72-week, phase III SURMOUNT-1 clinical trial the researchers have reported that combination GIP and GLP-1 receptor agonist tirzepatide...
Tirzepatide shows superior outcomes in type 2 diabetes without increasing hypoglycemia risk Medha Baranwal23 May 2022 2:30 PM GMTGreece: All doses of tirzepatide were found to be superior to placebo, insulin, and long-acting GLP-1 RAs in reducing HbA1c and body weight, according ...
'Twincretin' Tirzepatide Recieves FDA Approval for Type 2 Diabetes Dr. Nandita Mohan18 May 2022 5:00 AM GMTThe 'Twincretin' era for treating patients with type 2 diabetes has begun, with the US Food and Drug Administration's (FDA's) approval...
Eli Lilly Mounjaro injection gets USFDA nod for type 2 diabetes Ruchika Sharma14 May 2022 9:47 AM GMTMounjaro will be available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) and will come in Lilly's auto-injector pen with a pre-attached,...
FDA approves Tirzepatide for controlling blood sugar in type 2 diabetes patients Dr. Kamal Kant Kohli14 May 2022 6:45 AM GMTThe US Food and Drug Administratio has granted approval to tirzepatide (Mounjaro) injection for treatment of patients with type 2 diabetes. ...
Journal Club - Tirzepatide may lead weight loss of up to 23 percent in obese people Dr.B.P.RAHUL9 May 2022 10:03 AM GMTRecent data from SURMOUNT-1 clinical trial showed that tirzepatide achieved superior weight loss compared to a placebo in obese/overweight individuals ...
Tirzepatide may lead weight loss of up to 23 percent in obese people: SURMOUNT-1 trial Medha Baranwal3 May 2022 4:30 AM GMTUSA: Recent data from SURMOUNT-1 clinical trial showed that tirzepatide achieved superior weight loss compared to a placebo in obese/overweight...
Tirzepatide tied with Significant Reduction in Liver Fat Content in Patients with T2D: Study Dr. Shravani Dali30 April 2022 5:30 AM GMTTirzepatide Shows a Significant Reduction in Liver Fat Content in Patients with T2D, according to a recent study published in The Lancet Diabetes...
Tirzepatide bests insulin degludec for achieving blood sugar targets in type 2 diabetes: Lancet Medha Baranwal29 April 2022 3:30 AM GMTUSA: Once-weekly treatment with tirzepatide compared to insulin degludec led to superior glycemic control in patients with type 2 diabetes (T2D) on...
Tirzepatide plus insulin glargine improves blood sugar control in type 2 diabetes patients: SURPASS-5 trial Medha Baranwal12 Feb 2022 4:30 AM GMTUSA: The addition of once-weekly subcutaneous tirzepatide to insulin glargine may significantly improve blood sugar control versus placebo in patients ...
Tirzepatide aids weight loss, improves metabolic health in type 2 diabetes: Study Medha Baranwal24 Nov 2021 3:30 AM GMTUSA: Tirzepatide use in patients with type 2 diabetes (T2D) positively impacts metabolic profile that can only be partially attributed to weight loss, ...
